On September 7, 2022 Amgen (NASDAQ:AMGN) reported that it will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology Annual Congress (ESMO) (Free ESMO Whitepaper) at 1:30 p.m. ET on Monday, Sept. 12, 2022 (Press release, Amgen, SEP 7, 2022, View Source [SID1234619147]). David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen’s clinical development team, will discuss the data being presented from the LUMAKRAS (sotorasib) CodeBreaK 200 confirmatory Phase 3 study in non-small cell lung cancer and data from the full Phase 1b expansion cohort of LUMAKRAS in combination with Vectibix (panitumumab) in colorectal cancer. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast, as with other selected presentations regarding developments in Amgen’s business given by management at certain investor and medical conferences, can be found on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.